Orofacial Granulomatosis: Clinical Signs of Different Pathologies

Giuseppe Troiano\textsuperscript{a} Mario Dioguardi\textsuperscript{a} Giovanni Giannatempo\textsuperscript{a} Luigi Laino\textsuperscript{a} Nunzio Francesco Testa\textsuperscript{c} Roberto Cocchi\textsuperscript{b} Alfredo De Lillo\textsuperscript{a} Lorenzo Lo Muzio\textsuperscript{a}

\textsuperscript{a}Department of Clinical and Experimental Medicine, Foggia University, and \textsuperscript{b}Unit of Maxillofacial Surgery, Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Foggia, and \textsuperscript{c}Department of Translational Medicine, Bari University, Bari, Italy

**Introduction**

Orofacial granulomatosis (OFG) includes a group of diseases characterized by the presence of noncaseating granulomatous inflammation affecting the soft tissues of the oral and maxillofacial region \cite{1}. OFG may be the oral manifestation of a systemic condition such as inflammatory bowel disease (IBD), sarcoidosis, granulomatosis with polyangiitis (GPA) and Melkersson-Rosenthal syndrome (MRS) \cite{2–4}. These pathologies are part of a differential diagnosis of other granulomatous diseases, such as tuberculosis, leprosy, systemic fungal infections and foreign body reactions \cite{5}. The diagnosis of OFG is made by histopathological identification of noncaseating granulomas. Local and systemic conditions characterized by granulomatous inflammation should be excluded by appropriate clinical and laboratory investigations. In fact, the diagnosis of OFG may be confirmed only by histopathological identification of noncaseating granulomas. The literature from 1943 to 2014 was reviewed with emphasis on the etiology of OFG and on clinical manifestations of systemic pathologies associated with OFG. The precise cause of OFG is still unknown, although several theories have been suggested, such as infection, hereditary factors and allergy. OFG is a disease that has a wide spectrum of presentation, which may include the oral manifestation of a systemic condition such as Crohn's disease, sarcoidosis, granulomatosis with polyangiitis and Melkersson-Rosenthal syndrome.
Inflammatory Bowel Disease

IBD comprises two chronic clinical entities: Crohn’s disease (CD) and ulcerative colitis (UC), both immunologically based [7]. CD can cause transmural inflammation and affect any part of the gastrointestinal tract (most commonly, the terminal ileum or the perianal region) in a discontinuous type. CD is commonly associated with complications such as abscesses, fistulas and strictures, but UC is characterized by mucosal inflammation and limited to the colon [8–10]. The key factors responsible for IBD include genetic components, environmental factors, microbial flora and immune responses. IBD arises from an extremely complex interaction among genetic and environmental factors, dysregulated immune responses and alterations in the microbiota, but none of these factors alone is likely to cause the disease [11]. Bowel symptoms are predominant, but extraintestinal complications may occur in these pathologies, including the involvement of the oral cavity. CD and UC are commonly associated with abdominal pain, diarrhea, rectal bleeding, weight loss and signs of malnutrition [12]. Approximately one third of IBD patients develop extraintestinal manifestations in the course of their disease [13]. The most common extraintestinal manifestations involve the joints, skin, eyes and biliary tract [14].

The association between OFG and IBD was especially noted in CD rather than in other IBD events. Oral manifestations have a prevalence ranging from 20 to 50%, and initial presenting signs occur in 5–10% of affected patients (fig. 1a). Lesions are usually more severe during active disease, but up to 30% of patients may continue to manifest oral lesions despite disease control [15]. The most common intraoral site seems to be the lips. The oral manifestations of CD can be divided into specific and nonspecific lesions, based on the presence/absence of granuloma during the histopathological examination (table 1). Specific lesions are less common than nonspecific ones and, at histopathological examination, present typi
cal granuloma characteristics [16].

Sarcoidosis

Sarcoidosis is a systemic granulomatous disease of unknown cause affecting mostly young and middle-aged adults. The highest annual incidence of sarcoidosis has been observed in northern European countries (5–40 cases per 100,000 people) [21]. This pathology affects multiple organs, especially the lungs, lymph nodes, skin and eyes. Some studies confirm a genetic predisposition to sarcoidosis and present evidence for the allelic variation at the HLA-DRB1 locus as a major cause [22]. In the maxillofacial region, the salivary glands are often involved, and this may cause xerostomia or bilateral parotid swelling [23–25]. The involvement of the oral cavity seems to be rare with an unknown prevalence. Oral sarcoidosis usually appears in patients with chronic multisystemic sarcoidosis and presents as first manifestation of the disease in one third to almost two thirds of patients [26]. In 1943, Poe [27] reported the first documented case of oral sarcoidosis; since then,

Table 1. Specific and nonspecific oral lesions of CD

| Specific lesions                        | Nonspecific lesions                  |
|----------------------------------------|--------------------------------------|
| Indurated tag-like lesions             | Aphthous stomatitis                  |
| Cobblestoning                          | Pyostomatitis vegetans               |
| Mucogingivitis                         | Angular cheilitis                    |
| Lip swelling with vertical fissures    | Glossitis                            |
| Deep linear ulceration                 | Persistent submandibular lymphadenopathy |

reviewed in order to exclude irrelevant studies, and clinical opinion papers were excluded. Attention was paid to other articles that did not appear in the main search, by the reference lists of key articles in the field. Only English abstracts were included in the study. Following the preliminary identification of 123 articles, only 24 were identified as meeting the inclusion criteria. The following oral manifestations were observed: IBD, sarcoidosis, GPA and MRS.
there have been only 68 well-documented cases of isolated oral sarcoidosis reported in the English literature. These lesions were localized swellings or nodules (n = 34; fig. 1b), ulcers (n = 4), swelling with multiple ulcers (n = 2), gingivitis (n = 3), gingival hyperplasia (n = 3) and gingival recession (n = 1). In 24 cases, these oral lesions were the first manifestation of systemic sarcoidosis [28, 29].

Only some cases of oral sarcoidosis require treatment, because in nearly 60% of patients, the symptoms resolve spontaneously within 2 years. When lesions are localized, surgical excision is commonly employed, allowing both histopathological confirmation of sarcoidosis and treatment with systemic corticosteroids (fig. 1c, d) [30].

**Granulomatosis with Polyangiitis**

GPA is a systemic inflammatory disease characterized by necrotizing granulomatous inflammation and small-vessel vasculitis of the upper and lower respiratory tract and kidneys; however, other organs or tissues may be affected [31]. The world prevalence of GPA seems to be 23.7–156.5 cases per million [32], with an estimated annual incidence of 3.0–14.4 cases per million [33]. Oral manifestations of GPA range from 6 to 13% of patients, and the mouth may be the initial site of clinical presentation in 5–6% of cases [34, 35]. The most common oral manifestations of GPA are strawberry-like gingivitis, erythema, osteonecrosis of the palate, desquamation and nodular masses of the lips, petechiae and ulceration. Particularly strawberry-like gingivitis or hyperplastic gingival lesions are suggested to be a characteristic sign of GPA (fig. 1e) [36–38]. This sign consists of reddish-purple exophytic gingival swellings with petechial hemorrhages, thus similar to strawberries. This lesion can remain localized in the oral cavity for unusually long periods of time before multiorgan involvement occurs [39].
**Melkerson-Rosenthal Syndrome**

MRS is a rare, noncaseating granulomatous disease consisting of persistent or recurrent orofacial edema, relapsing peripheral facial paralysis and a fissured tongue [40]. Similar oral granulomatous reactions that are not associated with other detectable systemic diseases or foreign bodies may be present in Miescher’s cheilitis (MC). MC is a term used when lip swelling is the unique clinical sign (fig. 1f) [41]. MRS is also associated with some other syndromes, including trigeminal neuralgia, paresthesias, ocular palsies, blepharospasm, epiphora, keratitis, psychotic episodes, uveitis and migraine [42, 43]. MC may occur without other signs of the disease but may also be part of MRS; it could be a manifestation of CD and, rarely, of sarcoidosis. It is still debated whether MC should be considered as one of the extraintestinal manifestations of CD which can optionally be preceded by a few years of digestive problems or as a different disease entity. Van der Waal et al. [44], in a study of 13 MC cases, reported the appearance of gastrointestinal lesions of CD in 2 cases after a follow-up period of 2 years. This association has been supported by the results of another study [45]. Because of this association, in patients with MC, Pittock [46] recommended a screening for gastrointestinal lesions especially in children and young patients. The value of a systematic research of gastrointestinal lesions of MC has been reinforced by the fact that about one third of patients have evident HLA genotypes among the patients compared with the normal population, possibly of autosomal dominant transmission with incomplete penetration and translocation at chromosome 9p11 [51, 52]. It seems that consistent HLA genotypes are evident in patients with OFG, in particular A2/3, B7 and DR 2/3/4. These genotypes are known to occur in haplotype association. More studies are needed to validate these claims [53]. The possible role of infection in the pathogenesis of OFG has been suggested because of its involvement in CD and sarcoidosis [54]. Most studies have focused on *Mycobacterium tuberculosis*, *M. paratuberculosis*, *Staphylococcus aureus* and *Borrelia burgdorferi* [50–53]. Apaydin et al. [55] had used a ribosomal RNA amplification-based Gen-Probe amplified *M. tuberculosis* direct test to determine the presence of the *M. tuberculosis* complex in skin biopsy specimens from 5 patients with MRS and 1 patient with OFG. Three (all belonging to the MRS samples) of the 6 patients were positive; 1 of the positive specimens also showed positive Ziehl-Neelsen staining. *M. paratuberculosis* was investigated by Riggio et al. [56] in 1997 using polymerase chain reaction on 37 samples (30 OFG and 7 CD). The results of this study suggested that in this patient group, *M. paratuberculosis* did not appear to be associated with OFG or the oral lesions of CD [56]. *S. aureus* had been detected in mouths of 4 patients cultured using the oral rinse technique. It could represent a potential cause of panstomatitis in patients with OFG [57]. Some Chinese studies that evaluated the role of spirochetes in the etiology of OFG using Warthin-Starry special stain detected antibodies against *B. burgdorferi* in up to 82% of patients with cheilitis granulomatosa and MRS [58, 59]. However, Muellesgger et al. [60] who examined a retrospective study of 12 patients with OFG using polymerase chain reaction, ELISA and immunoblot test suggested that *B. burgdorferi* was not involved in the pathogenesis of OFG [60]. Hence, more studies are needed to clarify the role of this spirochete as an etiological factor of OFG.

**Etiology of OFG**

Introduced by Wiesenfeld et al. [2] in 1985, the term ‘etiologic of orofacial granulomatosis’ is used to describe diseases which have a variety of clinical presentations but also a similar histopathological picture to nonspecific, noncaseating granulomatous inflammation. OFG is either considered a different pathology or a manifestation of systemic disease [2, 50]. The precise cause of OFG is still unknown, although several theories have been suggested including infection, hereditary factors and allergy. A genetic predisposition has been evaluated in different studies; some of these suggested the occurrence of the disease in families and a frequent expression of some HLA antigens among the patients compared with the normal population, possibly of autosomal dominant transmission with incomplete penetration and translocation at chromosome 9p11 [51, 52]. It seems that consistent HLA genotypes are evident in patients with OFG, in particular A2/3, B7 and DR 2/3/4. These genotypes are known to occur in haplotype association. More studies are needed to validate these claims [53]. The possible role of infection in the pathogenesis of OFG has been suggested because of its involvement in CD and sarcoidosis [54]. Most studies have focused on *Mycobacterium tuberculosis*, *M. paratuberculosis*, *Staphylococcus aureus* and *Borrelia burgdorferi* [50–53]. Apaydin et al. [55] had used a ribosomal RNA amplification-based Gen-Probe amplified *M. tuberculosis* direct test to determine the presence of the *M. tuberculosis* complex in skin biopsy specimens from 5 patients with MRS and 1 patient with OFG. Three (all belonging to the MRS samples) of the 6 patients were positive; 1 of the positive specimens also showed positive Ziehl-Neelsen staining. *M. paratuberculosis* was investigated by Riggio et al. [56] in 1997 using polymerase chain reaction on 37 samples (30 OFG and 7 CD). The results of this study suggested that in this patient group, *M. paratuberculosis* did not appear to be associated with OFG or the oral lesions of CD [56]. *S. aureus* had been detected in mouths of 4 patients cultured using the oral rinse technique. It could represent a potential cause of panstomatitis in patients with OFG [57]. Some Chinese studies that evaluated the role of spirochetes in the etiology of OFG using Warthin-Starry special stain detected antibodies against *B. burgdorferi* in up to 82% of patients with cheilitis granulomatosa and MRS [58, 59]. However, Muellesgger et al. [60] who examined a retrospective study of 12 patients with OFG using polymerase chain reaction, ELISA and immunoblot test suggested that *B. burgdorferi* was not involved in the pathogenesis of OFG [60]. Hence, more studies are needed to clarify the role of this spirochete as an etiological factor of OFG.

Allergy in the form of hay fever, atopic eczema or asthma has been reported as being more prevalent, affecting 12–60% of OFG patients compared to 15% in the general population [61, 62]. Many diseases affecting the orofacial region have an allergic basis, and the role of dietary antigens, in particular in the etiopathogenesis of OFG, seems to be compelling [63]. Examples include cinnamon and benzoates which were positive on patch
tests in patients with a variety of oral mucosal diseases including OFG [64]. A study of 48 patients with OFG who were patch tested for their reaction to common food additives showed that 10 had a positive skin reaction and showed improvement in their OFG with an elimination diet [62, 65]. Occasionally, even delayed hypersensitivity to dental materials had been implicated in the etiology of OFG. Granulomatous reactions have been found in amalgam tattoos and in subcutaneous deposits of inorganic mercury [66, 67]. One study assessing the utility of the cutaneous patch test showed that patients with OFG had more reactions to food additives, especially benzoic acid and chocolate, than other disease co-

**Conclusion**

OFG is a disease with a wide spectrum of presentations. OFG may be the oral manifestation of a systemic condition, such as IBD, sarcoidosis, GPA and MRS. The precise cause of OFG is still unknown. However, several theories have suggested an important role for infection, hereditary factors and allergy.

**References**

1 Scibbja J, Said-Al-Naief N: Orofacial granulomatosis: presentation, pathology and management of 13 cases. J Oral Pathol Med 2003; 32:576–585.

2 Wiesenfeld D, Ferguson MM, Mitchell DN, et al: Oro-facial granulomatosis – a clinical and pathological analysis. Q J Med 1985;54:101–113.

3 Girlich C, Bogenrieder T, Palitzsch KD, et al: Orofacial granulomatosis as initial manifestation of Crohn’s disease: a report of two cases. Eur J Gastroenterol Hepatol 2002;14:873–876.

4 Mignogna MD, Fedele S, Lo Russo L, et al: Orofacial granulomatosis with gingival onset. J Clin Periodontol 2001;28:692–696.

5 Alawi F: Granulomatous diseases of the oral tissues: differential diagnosis and update. Dent Clin North Am 2005;49:203–221, x.

6 Rana AP: Orofacial granulomatosis: a case report with review of literature. J Indian Soc Periodontol 2012;16:469–474.

7 Trost LB, McDonnell JK: Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005;81:580–585.

8 Abraham C, Cho JH: Inflammatory bowel disease. N Engl J Med 2009;361:2066–2078.

9 Katsinelos P, Tziomalos K, Fasoulas K, et al: Can capsule endoscopy be used as a diagnostic tool in the evaluation of nonbleeding indications in daily clinical practice? A prospective study. Med Princ Pract 2011;20:362–367.

10 Spencer AJ: An evidence-based approach to the prevention of oral diseases. Med Princ Pract 2003;12(suppl 3):1–11.

11 Zhang YZ, Li YY: Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014;20:91–99.

12 Lourenco SV, Hussein TP, Bologna SB, et al: Oral manifestations of inflammatory bowel disease: a review based on the observation of six cases. J Eur Acad Dermatol Venereol 2010; 24:204–207.

13 Armond MC, Carlos RG, Pazzini CA, et al: Crohn’s disease: clinical manifestations of orthodontic interest. Am J Orthod Dentofacial Orthop 2011;139:704–707.

14 Levine JS, Burakoff R: Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (NY) 2011;7:235–241.

15 Lankarani KB, Siavazdadeh GR, Hassanpour S: Oral manifestation in inflammatory bowel disease: a review. World J Gastroenterol 2013; 19:8571–8579.

16 Plauth M, Jenss H, Meyle J: Oral manifestations of Crohn’s disease. An analysis of 79 cases. J Clin Gastroenterol 1991;13:29–37.

17 Harry S, Fleming P, Rowland M, et al: A prospective study of the oral manifestations of Crohn’s disease. Clin Gastroenterol Hepatol 2005;3:886–891.

18 Williams AJ, Wray D, Ferguson A: The clinical entity of orofacial Crohn’s disease. Q J Med 1999;79:451–458.

19 Harikishan G, Reddy NR, Prasad H, et al: Oral Crohn’s disease without intestinal manifestations. J Pharm Bioallied Sci 2012;4:541–543.

20 Katz J, Shenkman A, Stavropoulos F, et al: Oral signs and symptoms in relation to disease activity and site of involvement in patients with inflammatory bowel disease. Oral Dis 2003;9:34–40.

21 Pietinalho A, Hiraga Y, Hosoda Y, et al: The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 1995;12:61–67.

22 Rossman MD, Thompson B, Frederick M, et al: HLA-DRBI*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003;73:720–735.

23 Clayman L, MacLennan M, Dolan RL: Non-painful swelling of the palate and loosening of the maxillary incisors. J Oral Maxillofac Surg 1998;56:1327–1335.

24 Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 2007;357:2153–2165.

25 Abul A, Onadeko BO, Khadadah ME, et al: Clinical patterns of diffuse parenchymal lung disease in Kuwait: a prospective study. Med Princ Pract 2004;13:78–83.

26 Jackowski J, Dragisic D, Arnold G, et al: Primary oral sarcoidosis preceding Löfgren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:183–185.

27 Poe DL: Sarcoidosis of the jaw – a new disease of the mandible. Am J Orthod Dentofacial Orthop 1943;29:52–56.

28 Suresh L, Radfar L: Oral sarcoidosis: a review of literature. Oral Dis 2005;11:138–145.

29 Bouaziz A, Le Scannf J, Chapelon-Abric C, et al: Oral involvement in sarcoidosis: Report of 12 cases. QJM 2012;105:755–767.

30 Kasamatsu A, Kanazawa W, Watanabe T, et al: Oral sarcoidosis: report of a case and review of literature. J Oral Maxillofac Surg 2007;65:1256–1259.

31 Almouhawis HA, Leao JC, Fedele S, et al: Wegener’s granulomatosis: a review of clinical features and an update in diagnosis and treatment. J Oral Pathol Med 2013;42:507–516.

32 Abdou NI, Kullman GI, Hoffman GS, et al: Wegener’s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 2002;29:309–316.

33 Reinhold-Keller E, Herlyn K, Wagner-Bastmeier R, et al: Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005;53:93–99.

34 Ponniah I, Shaheen A, Shankar KA, et al: Wegener’s granulomatosis: the current understanding. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:265–270.

35 Patten SF, Tomecki JK: Wegener’s granulomatosis: cutaneous and oral mucosal disease. J Am Acad Dermatol 1993;28:710–718.

36 Bachmeyer C, Petjean B, Testart F, et al: Lingual necrosis as the presenting sign of Wegener’s granulomatosis. Clin Exp Dermatol 2006;31:321–322.
